GeneDx Holdings Corp. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GeneDx Holdings Corp. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $19.00K.
- GeneDx Holdings Corp. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $457.00K, a 96.71% decline year-over-year.
- GeneDx Holdings Corp. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $21.14M, a 33.76% decline year-over-year.
- GeneDx Holdings Corp. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $11.80M, a 19.10% decline year-over-year.
- GeneDx Holdings Corp. stock issued during period, value, new issues for fiscal 2025 was $46.70M, a 0.45% increase from fiscal 2024.
- GeneDx Holdings Corp. stock issued during period, value, new issues for fiscal 2024 was $46.50M.
- GeneDx Holdings Corp. stock issued during period, value, new issues for fiscal 2022 was $197.66M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $33.41M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $457.00K 10-Q · filed 2026-05-04 | $33.27M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $21.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $46.70M 10-K · filed 2026-02-23 |
| 2025-09-30 | $11.80M 10-Q · filed 2025-10-28 | $57.48M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$128.00K 10-Q · filed 2026-08-03 | $60.26M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $13.89M 10-Q · filed 2026-05-04 | |
| 2024-12-31 | $31.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $46.50M 10-K · filed 2026-02-23 |
| 2024-09-30 | $14.59M 10-Q · filed 2025-10-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $143.00M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $7.56M 10-Q · filed 2024-07-30 | $143.00M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $135.44M 10-Q · filed 2023-05-09 | $333.10M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $197.66M 10-K · filed 2024-02-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | |
| 2022-06-30 | $197.66M 10-Q · filed 2023-08-08 | |
| 2020-12-31 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-30 | |
| 2020-09-30 | $25.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |